Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
Delayed Nyse  -  01:00 2022-11-25 pm EST
11.90 USD   +0.59%
11/16SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
AQ
11/14Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
GL
11/14Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Emergent BioSolutions Completes Acquisition of Rights to Smallpox Oral Antiviral Tembexa

09/26/2022 | 04:41pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CHIMERIX, INC. -1.79% 2.2 Delayed Quote.-65.79%
EMERGENT BIOSOLUTIONS INC. 0.59% 11.9 Delayed Quote.-72.62%
All news about EMERGENT BIOSOLUTIONS INC.
11/16SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
AQ
11/14Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vacc..
GL
11/14Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vacc..
GL
11/11North American Morning Briefing: Fed Hopes, China -3-
DJ
11/09Health Care Down on Inflation Resilience -- Health Care Roundup
DJ
11/09Emergent Biosolutions Q3 Adjusted Loss Widens, Revenue Falls; Cuts Full-Year Revenue Ou..
MT
11/09Chardan Cuts Price Target on Emergent Biosolutions to $55 From $65 on Slower Revenue, P..
MT
11/08Emergent Biosolutions : Q3 Earnings Snapshot
AQ
11/08Transcript : Emergent BioSolutions Inc., Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Emergent Biosolutions Inc. : Results of Operations and Financial Condition, Regulation FD ..
AQ
More news
Analyst Recommendations on EMERGENT BIOSOLUTIONS INC.
More recommendations
Financials (USD)
Sales 2022 1 100 M - -
Net income 2022 -191 M - -
Net Debt 2022 831 M - -
P/E ratio 2022 -3,06x
Yield 2022 -
Capitalization 594 M 594 M -
EV / Sales 2022 1,29x
EV / Sales 2023 1,09x
Nbr of Employees 2 416
Free-Float 80,8%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Last Close Price 11,90 $
Average target price 31,40 $
Spread / Average Target 164%
EPS Revisions
Managers and Directors
Robert G. Kramer Chief Financial Officer
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Zsolt Pßl Harsßnyi Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Christopher H. Cabell Chief Medical Officer & Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-72.62%594
JOHNSON & JOHNSON3.61%463 391
ELI LILLY AND COMPANY30.95%347 052
ABBVIE INC.17.89%282 189
PFIZER, INC.-16.66%276 231
MERCK & CO., INC.40.27%272 555